LARGE SERINE RECOMBINASES, SYSTEMS AND USES THEREOF
The present invention provides novel serine recombinases, recombinase based systems and compositions, and methods for genomic targeting and modification. In some aspects, the large serine recombinases, and systems thereof are used to treat human diseases.
1 . A system for modifying DNA, the system comprising:
(a) a large serine recombinase having at least 70% identity to any one of the amino acid sequences listed in SEQ ID NOs: 1-774;
(b) a DNA recognition sequence comprising an attP or an attB attachment site; and/or
(c) a heterologous DNA sequence.
2 . The system of claim 1 , wherein the large serine recombinase has at least 80%, 85%, 90%, 95% or greater identity to any one of the amino acid sequences listed in SEQ ID NOs: 1-774.
3 . The system of claim 1 , wherein the large serine recombinase has at least 99% identity to any one of the amino acid sequences listed in SEQ ID NOs: 1-774.
4 . The system of claim 1 , wherein the large serine recombinase has 100% identity to any one of the amino acid sequences listed in SEQ ID NOs: 1-774.
5 . The system of any one of the preceding claims , wherein the large serine recombinase has at least 70% identity to any one of polynucleotide sequences listed in SEQ ID NOs: 775-1548.
6 . The system of any one of the preceding claims , wherein the large serine recombinase has at least 80%, 85%, 90%, 95% or greater identity to any one of the polynucleotide sequences listed in SEQ ID NOs: 775-1548.
7 . The system of any one of the preceding claims , wherein the large serine recombinase has at least 99% identity to any one of the polynucleotide sequences listed in SEQ ID NOs: 775-1548.
8 . The system of any one of the preceding claims , wherein the large serine recombinase has 100% identity to any one of the polynucleotide sequences listed in SEQ ID NOs: 775-1548.
9 . The system of any one of the preceding claims , wherein the large serine recombinase is derived from a phage or bacterial genome.
10 . The system of claim 9 , wherein the phage or bacterial species is any one of the sources listed in SEQ ID NOs: 1-774.
11 . The system of any one of the preceding claims , wherein the system comprises an attP site that recognizes a cognate attB site in the genome and causes recombination integrating the heterologous DNA in the genome.
12 . The system of any one of the preceding claims , wherein the system comprises an attB site that recognizes a cognate attP site in the genome and causes recombination integrating the heterologous DNA in the genome.
13 . The system of any one of the preceding claims , wherein the attP or attB site comprises a parapalindromic sequence.
14 . The system of any one of the preceding claims , wherein the attP or attB sites are naturally occurring, i.e., pseudo attP or pseudo attB sites.
15 . The system of any one of the preceding claims , wherein the attP or attB sites are engineered or optimized for expression in a target cell.
16 . The system of any one of the preceding claims , wherein the heterologous DNA sequence is recombined or inserted into the target genome at one or more attP or attB sites.
17 . The system of claim 16 , wherein the heterologous DNA sequence is recombined or inserted into the target genome at a single attP or attB site.
18 . The system of any one of the preceding claims comprised in one or more integrative vectors.
19 . The system of claim 18 , wherein the system is comprised in a single integrative vector.
20 . The system of claim 18 or 19 , wherein the vector is an adeno-associated virus (AAV) or lentivirus vector.
21 . A method for modulating a genome in a cell, the method comprising:
(a) contacting the cell with a polypeptide encoding a serine recombinase enzyme having at least 70% identity to any one of the amino acid sequences listed in SEQ ID NOs: 1-774;
(b) a DNA recognition sequence comprising a first and a second attachment site; and/or
(c) a heterologous DNA sequence;
wherein the serine recombinase enzyme mediates site-specific recombination between the first and the second attachment site causing integration of heterologous DNA, thereby modulating the genome.
22 . The method of claim 21 , wherein at least one site is a pseudo attachment site.
23 . The method of claim 21 , wherein one or more sites is an engineered site.
24 . The method of claim 23 , wherein the first and second attachment sites are attP or attB sites.
25 . The method of claim 24 , wherein the attB site is in a target genome and the attP site sequence is in an integrative vector.
26 . The method of claim 24 , wherein the attP site sequence is in a target genome and the attB site sequence is in an integrative vector.
27 . The method of any one of the preceding claims , wherein the site-specific recombination occurs at one or more sites in the cell.
28 . The method of any one of the preceding claims , wherein the site-specific recombination occurs at a single site in the cell.
29 . The method of any one of claims 21-28 , wherein the site-specific recombination results in expression of a heterologous gene.
30 . The method of any one of the preceding claims , wherein the recombination is carried out in a mammalian cell.
31 . The method of claim 30 , wherein the recombination is carried out in a human cell.
32 . The method of any one of the preceding claims , wherein the recombination is carried out in a cultured cell.
33 . The method of any one of claims 21-32 , wherein the recombination is carried out in a primary cell.
34 . The method of any one of the preceding claims , wherein the recombination is carried out in a non-dividing cell.
35 . The method of any one of the preceding claims , wherein the recombination is carried out in an immune cell.
36 . The cell of claim 35 , wherein the immune cell is a T-cell, B-cell or NK cell.
37 . The method of any one of the preceding claims , wherein the recombination is carried out in vivo.
38 . The method of claim 37 , wherein the in vivo recombination treats a genetic disease by repairing a genetic mutation and/or restoring a functional gene.
39 . The method of claim 38 , wherein the in vivo recombination treats a cancer by delivering a lethal or conditional lethal gene.
40 . The method of claim 39 , wherein the in vivo recombination results in genome editing by introducing one or more enzymes selected from a group consisting of a Cas enzyme, a base editor, deaminase and a reverse transcriptase.
41 . The method of any one of claims 21-40 , wherein the serine recombinase directs stable integration of the heterologous DNA.
42 . The method of any one of claims 21-40 , wherein the serine recombinase directs reversible integration of the heterologous DNA.
43 . The method of any one of the preceding claims , wherein the heterologous DNA further comprises a Recombinase Directionality Factor (RDF) leading to excision of integrated DNA from the genome.
44 . The method of any one of the preceding claims , wherein the promoter is constitutive or inducible.
45 . The method of any one of the preceding claims , wherein the heterologous DNA integrated is between about 2 kb to about 40 kb in length.
46 . An engineered cell produced by the method of any one of the preceding claims 21-45 .
47 . A method of treating a genetic disease or cancer, wherein the engineered cell of claim 46 is administered to a patient in need thereof.
48 . The attP attachment site of claim 1 , wherein the site comprises between 30 to 75 contiguous nucleotides from any one of SEQ ID NOs: 1549-2322, corresponding to its cognate LSR sequence as described in Table 3.